Full Press Release Details
PITTSBURGH , May 22, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ), a global healthcare company, today announced that as part of its ongoing board refreshment efforts, Leo Groothuis has been appointed as Viatris' newest member of its board of directors. Groothuis fills the vacancy created by the previous departure of Michael Goettler in April of this year.
Groothuis has significant international experience and serves as General Counsel of HAL Investments, the Dutch investment subsidiary of HAL Holding N.V., an international investment company listed on the Amsterdam stock exchange, which is focused on increasing shareholder value. In addition to his strategic, financial and governance focus, he has also been actively involved in the development and execution of HAL Investments' ESG strategy.
Throughout his career, Groothuis has been a trusted C-suite and board advisor to some of the largest companies in both Europe and the U.S. Prior to his role at HAL Investments, he served as practice leader at NautaDutilh, an international law firm, where he guided numerous multi-national companies on significant and complex transactions. As a result, he is recognized as a top lawyer and thought leader in corporate governance, capital markets and M&A.
Viatris Executive Chairman Robert J. Coury said, "We are extremely pleased to welcome Leo Groothuis , a recognized top international executive to the Viatris board. We believe his proven strategic, corporate governance and capital markets experience should serve as a tremendous asset for Viatris, as we continue to look for ways to build and unlock value for our shareholders."
About Viatris Viatris Inc. (NASDAQ: VTRS ) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020 , Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines and a variety of over-the-counter consumer products. With more than 38,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh , Shanghai and Hyderabad, India . Learn more at viatris.com and investor.viatris.com , and connect with us on Twitter , LinkedIn , Instagram and YouTube .